{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:12:58Z","timestamp":1794013978997,"version":"4.8.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008275","name":"University of Florida Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007698","name":"University of Florida","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007698","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA266659"],"award-info":[{"award-number":["CA266659"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.gendis.2024.101452","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T09:22:27Z","timestamp":1730971347000},"page":"101452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Targeting METTL3 protein by proteolysis-targeting chimeras: A novel therapeutic approach for acute myeloid leukemia"],"prefix":"10.1016","volume":"12","author":[{"given":"Rukiye","family":"Nar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5624-8003","authenticated-orcid":false,"given":"Zhixing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1645-1995","authenticated-orcid":false,"given":"Yafang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0200-6751","authenticated-orcid":false,"given":"Alexis","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9010-9461","authenticated-orcid":false,"given":"Fang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanhui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2161-3394","authenticated-orcid":false,"given":"Chunjie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguang","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangrong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.gendis.2024.101452_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","article-title":"Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance","volume":"127","author":"Grimwade","year":"2016","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.gendis.2024.101452_bib4","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.gendis.2024.101452_bib5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41392-020-00361-x","article-title":"Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy","volume":"5","author":"Carter","year":"2020","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.gendis.2024.101452_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106314","article-title":"Venetoclax combination therapy in relapsed\/refractory acute myeloid leukemia: a single institution experience","volume":"90","author":"Gaut","year":"2020","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.gendis.2024.101452_bib7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.gendis.2024.101452_bib8","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.gendis.2024.101452_bib9","unstructured":"Recent trends in SEER age-adjusted incidence rates, 2000-2020. Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=1&data_type=1&graph_type=2&compareBy=sex&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0."},{"issue":"6409","key":"10.1016\/j.gendis.2024.101452_bib10","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1126\/science.aau1646","article-title":"RNA modifications modulate gene expression during development","volume":"361","author":"Frye","year":"2018","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.gendis.2024.101452_bib11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12943-020-01204-7","article-title":"The potential role of RNA N6-methyladenosine in cancer progression","volume":"19","author":"Wang","year":"2020","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2024.101452_bib12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12943-023-01810-1","article-title":"Epigenetic modification of m6A regulator proteins in cancer","volume":"22","author":"Wang","year":"2023","journal-title":"Mol Cancer"},{"issue":"8","key":"10.1016\/j.gendis.2024.101452_bib13","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3390\/biom12081042","article-title":"Multifaceted roles of the N6-methyladenosine RNA methyltransferase METTL3 in cancer and immune microenvironment","volume":"12","author":"Hu","year":"2022","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.gendis.2024.101452_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006188","article-title":"RNA modifications go viral","volume":"13","author":"Gokhale","year":"2017","journal-title":"PLoS Pathog"},{"issue":"1","key":"10.1016\/j.gendis.2024.101452_bib15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ejhf.1672","article-title":"Changes in m6A RNA methylation contribute to heart failure progression by modulating translation","volume":"22","author":"Berulava","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"7683","key":"10.1016\/j.gendis.2024.101452_bib16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nature24678","article-title":"Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control","volume":"552","author":"Barbieri","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.gendis.2024.101452_bib17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.stem.2017.11.016","article-title":"METTL14 inhibits hematopoietic stem\/progenitor differentiation and promotes leukemogenesis via mRNA m6A modification","volume":"22","author":"Weng","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"7724","key":"10.1016\/j.gendis.2024.101452_bib18","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-018-0538-8","article-title":"mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis","volume":"561","author":"Choe","year":"2018","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.gendis.2024.101452_bib19","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/nm.4416","article-title":"The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells","volume":"23","author":"Vu","year":"2017","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.gendis.2024.101452_bib20","doi-asserted-by":"crossref","first-page":"12738","DOI":"10.1021\/acs.jmedchem.1c00773","article-title":"1, 4, 9-triazaspiro[5.5]undecan-2-one derivatives as potent and selective METTL3 inhibitors","volume":"64","author":"Dolbois","year":"2021","journal-title":"J Med Chem"},{"issue":"7860","key":"10.1016\/j.gendis.2024.101452_bib21","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","article-title":"Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia","volume":"593","author":"Yankova","year":"2021","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.gendis.2024.101452_bib22","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41594-021-00606-5","article-title":"Mining for METTL3 inhibitors to suppress cancer","volume":"28","author":"Li","year":"2021","journal-title":"Nat Struct Mol Biol"},{"issue":"3","key":"10.1016\/j.gendis.2024.101452_bib23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.molcel.2016.03.021","article-title":"The m6A methyltransferase METTL3 promotes translation in human cancer cells","volume":"62","author":"Lin","year":"2016","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.gendis.2024.101452_bib24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.gendis.2024.101452_bib25","first-page":"41","article-title":"Proteolysis-targeting chimeras: harnessing the ubiquitin-proteasome system to induce degradation of specific target proteins","volume":"2","author":"Coleman","year":"2018","journal-title":"Annu Rev Cell Biol"},{"issue":"26","key":"10.1016\/j.gendis.2024.101452_bib26","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1038\/s41388-020-1336-y","article-title":"PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics","volume":"39","author":"Khan","year":"2020","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.gendis.2024.101452_bib27","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/bph.15014","article-title":"Proteolysis-targeting chimeras in drug development: a safety perspective","volume":"177","author":"Moreau","year":"2020","journal-title":"Br J Pharmacol"},{"issue":"12","key":"10.1016\/j.gendis.2024.101452_bib28","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem Soc Rev"},{"issue":"12","key":"10.1016\/j.gendis.2024.101452_bib29","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.molcel.2023.05.010","article-title":"RBM33 is a unique m6A RNA-binding protein that regulates ALKBH5 demethylase activity and substrate selectivity","volume":"83","author":"Yu","year":"2023","journal-title":"Mol Cell"},{"issue":"26","key":"10.1016\/j.gendis.2024.101452_bib30","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood.2021011707","article-title":"A critical role of nuclear m6A reader\u00a0YTHDC1 in leukemogenesis by regulating MCM complex-mediated DNA replication","volume":"138","author":"Sheng","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.gendis.2024.101452_bib31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41467-018-08027-7","article-title":"Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase","volume":"10","author":"Smith","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.gendis.2024.101452_bib32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/emboj\/19.1.94","article-title":"Recognition of the polyubiquitin proteolytic signal","volume":"19","author":"Thrower","year":"2000","journal-title":"EMBO J"},{"issue":"10","key":"10.1016\/j.gendis.2024.101452_bib33","doi-asserted-by":"crossref","first-page":"5779","DOI":"10.1093\/nar\/gkab415","article-title":"Post-translational modification of RNA m6A demethylase ALKBH5 regulates ROS-induced DNA damage response","volume":"49","author":"Yu","year":"2021","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"10.1016\/j.gendis.2024.101452_bib34","first-page":"105","article-title":"Interferences in immunoassay","volume":"25","author":"Tate","year":"2004","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.gendis.2024.101452_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs) - past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov Today Technol"},{"issue":"5","key":"10.1016\/j.gendis.2024.101452_bib36","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40259-022-00551-9","article-title":"PROTACs: current trends in protein degradation by proteolysis-targeting chimeras","volume":"36","author":"Madan","year":"2022","journal-title":"BioDrugs"},{"issue":"8","key":"10.1016\/j.gendis.2024.101452_bib37","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.7150\/ijbs.70335","article-title":"METTL3 promotes cell cycle progression via m6A\/YTHDF1-dependent regulation of CDC25B translation","volume":"18","author":"Li","year":"2022","journal-title":"Int J Biol Sci"},{"issue":"1","key":"10.1016\/j.gendis.2024.101452_bib38","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12964-023-01360-5","article-title":"New insights into the regulation of METTL3 and its role in tumors","volume":"21","author":"Jin","year":"2023","journal-title":"Cell Commun Signal"},{"issue":"1","key":"10.1016\/j.gendis.2024.101452_bib39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-022-00256-3","article-title":"METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression","volume":"11","author":"Guo","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"10.1016\/j.gendis.2024.101452_bib40","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.7150\/jca.60381","article-title":"The m6A RNA methyltransferase METTL3\/METTL14 promotes leukemogenesis through the mdm2\/p53 pathway in acute myeloid leukemia","volume":"13","author":"Sang","year":"2022","journal-title":"J Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2024.101452_bib41","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.gendis.2024.101452_bib42","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s42255-019-0089-9","article-title":"m6A mRNA\u00a0methylation regulates human \u03b2-cell biology in physiological states and in type 2 diabetes","volume":"1","author":"De","year":"2019","journal-title":"Nat Metab"},{"issue":"11","key":"10.1016\/j.gendis.2024.101452_bib43","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/s41375-022-01696-w","article-title":"METTL3 mediates chemoresistance by enhancing AML homing and engraftment via ITGA4","volume":"36","author":"Li","year":"2022","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.gendis.2024.101452_bib44","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1101\/gad.301036.117","article-title":"m6A mRNA modifications are deposited in nascent pre-mRNA and are not required for splicing but do specify cytoplasmic turnover","volume":"31","author":"Ke","year":"2017","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.gendis.2024.101452_bib45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/10428194.2018.1464158","article-title":"MYC protein expression is an important prognostic factor in acute myeloid leukemia","volume":"60","author":"Ohanian","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.gendis.2024.101452_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.584974","article-title":"Targeting Bcl-2 proteins in acute myeloid leukemia","volume":"10","author":"Wei","year":"2020","journal-title":"Front Oncol"},{"issue":"15","key":"10.1016\/j.gendis.2024.101452_bib47","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2020001920","article-title":"American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults","volume":"4","author":"Sekeres","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.gendis.2024.101452_bib48","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chembiol.2023.12.009","article-title":"Discovery of a PROTAC degrader for METTL3-METTL14 complex","volume":"31","author":"Du","year":"2024","journal-title":"Cell Chem Biol"},{"issue":"2","key":"10.1016\/j.gendis.2024.101452_bib49","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1021\/jacsau.4c00040","article-title":"Proteolysis Targeting Chimera Degraders of the METTL3-14 m6A-RNA Methyltransferase","volume":"4","author":"Errani","year":"2024","journal-title":"JACS Au"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304224002496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304224002496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T11:33:34Z","timestamp":1746444814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304224002496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2352304224002496"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2024.101452","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting METTL3 protein by proteolysis-targeting chimeras: A novel therapeutic approach for acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2024.101452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd\u00e9","name":"copyright","label":"Copyright"}],"article-number":"101452"}}